Comparative Pharmacology
Head-to-head clinical analysis: FERAHEME versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERAHEME versus SESQUIENT.
FERAHEME vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement